Page last updated: 2024-08-22

camptothecin and dalteparin

camptothecin has been researched along with dalteparin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alexander, J; Becker, RC; Bovill, E; Dyke, CK; Harrington, RA; Kunitada, S; Li, YF; Robertson, TL; Spencer, FA	1
Benson, AB; Berlin, J; Burtness, B; Catalano, P; Chapman, AE; Liles, DK; Mitchell, E; Powell, M	1
Bonetti, A; Giuliani, J; Martelli, S; Piacentini, P	1

Trials

1 trial(s) available for camptothecin and dalteparin

Article	Year
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. American journal of clinical oncology, 2016, Volume: 39, Issue:4 Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cetuximab; Diarrhea; Disease-Free Survival; Docetaxel; Enoxaparin; Female; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids; Thromboembolism	2016

Article

Year

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.

American journal of clinical oncology, 2016, Volume: 39, Issue:4

Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cetuximab; Diarrhea; Disease-Free Survival; Docetaxel; Enoxaparin; Female; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids; Thromboembolism

2016

Other Studies

2 other study(ies) available for camptothecin and dalteparin

Article	Year
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. Thrombosis and haemostasis, 2004, Volume: 92, Issue:6 Topics: Anticoagulants; Blood Coagulation Tests; Calcium Chloride; Camptothecin; Drug Synergism; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Sensitivity and Specificity	2004
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis". Tumori, 2015, Mar-20, Volume: 101, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Collateral Circulation; Colorectal Neoplasms; Disease Progression; Enoxaparin; Fatal Outcome; Female; Fibrinolytic Agents; Fluorouracil; Humans; Leucovorin; Middle Aged; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Venous Thromboembolism	2015

Article

Year

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.

Thrombosis and haemostasis, 2004, Volume: 92, Issue:6

Topics: Anticoagulants; Blood Coagulation Tests; Calcium Chloride; Camptothecin; Drug Synergism; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Sensitivity and Specificity

2004

Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".

Tumori, 2015, Mar-20, Volume: 101, Issue:1

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Collateral Circulation; Colorectal Neoplasms; Disease Progression; Enoxaparin; Fatal Outcome; Female; Fibrinolytic Agents; Fluorouracil; Humans; Leucovorin; Middle Aged; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Venous Thromboembolism

2015